Myasthenia Gravis

Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.

It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.


Clinical trial ongoing at the Institute:

  • RA101495-02.301 : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis




Study type RIPH1
Intervention Zilucoplan
Principal investigator Anthony Behin
Sponsor RAPharma
Fundings RAPharma
Study status In preparation
Recruitment status In preparation
Population Adult
  + infos on